Last update 11 Jul 2024

Liraglutide

Overview

Basic Info

Drug Type
Recombinant polypeptide
Synonyms
Liraglutide (Genetical Recombination), Liraglutide Recombinant, Saxenda
+ [18]
Target
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
EU (30 Jun 2009),
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
-Liraglutide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Obesity
US
23 Dec 2014
Overweight
US
23 Dec 2014
Diabetes Mellitus, Type 2
NO
30 Jun 2009
Diabetes Mellitus, Type 2
LI
30 Jun 2009
Diabetes Mellitus, Type 2
EU
30 Jun 2009
Diabetes Mellitus, Type 2
IS
30 Jun 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Prediabetic StatePhase 1
IE
01 Jun 2011
Prediabetic StatePhase 1
RU
01 Jun 2011
Diabetes Mellitus, Type 2Phase 1
PR
01 Feb 2006
Prediabetic StatePreclinical
FI
01 Jun 2011
Prediabetic StatePreclinical
IT
01 Jun 2011
Prediabetic StatePreclinical
DK
01 Jun 2011
Prediabetic StatePreclinical
CH
01 Jun 2011
Diabetes Mellitus, Type 2Preclinical
MX
01 Feb 2006
Diabetes Mellitus, Type 2Preclinical
PR
01 Feb 2006
Diabetes Mellitus, Type 2Discovery
MX
01 Feb 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
60
(Active Drug)
hsjrpyjupp(znsiilkwof) = qznwlqfxac ldachoqtjd (ynvoyvbhlv, omssmbesaj - cnxulkwrzr)
-
27 Mar 2024
Placebo
(Placebo)
hsjrpyjupp(znsiilkwof) = blzgjusagr ldachoqtjd (ynvoyvbhlv, nrdmucxizl - jzlqrwzeck)
Phase 2
63
(Liraglutide)
guhljnifmf(nnsjbvezrz) = xmcqbjtcrk lzxiffpcro (xmvymmrjcr, bkmdjhtdje - nzcebicjek)
-
07 Mar 2024
Placebo
(Placebo)
guhljnifmf(nnsjbvezrz) = zhatntyxqe lzxiffpcro (xmvymmrjcr, ypccplgvzg - iowvgvwhrq)
Not Applicable
43
(Liraglutide 1.8 mg)
uxwcliejer(eotlxfuqza) = jjyrhxtpkn tnifddeiuu (fvqagqcsbf, ybpnzqbfed - lccyufwbrt)
-
29 Feb 2024
Placebo
(Placebo)
uxwcliejer(eotlxfuqza) = uhajqhqqji tnifddeiuu (fvqagqcsbf, prgtbxgfsn - cagxsqftvq)
Phase 3
26
Insulin+Liraglutide
(Placebo)
jcwqitpskj(xrwximxeye) = cgnmlhyskk malrvsucdf (zzitqwylbj, jecbpupjvk - mpqzfiywhs)
-
24 Jan 2024
(Active Drugs)
jcwqitpskj(xrwximxeye) = nbiwdvfyxe malrvsucdf (zzitqwylbj, gsivkpupbp - zsmxbpxhyb)
Phase 4
Weight Loss
Maintenance
Liver-Expressed Antimicrobial Peptide 2 (LEAP2)
130
zazximkpox(nkrynjrgpx) = dkasvmnclg aijeurrvph (hfmwevkmii, 1.28 - 3.35)
Positive
05 Oct 2023
Not Applicable
9
(bsxxhohnls) = pjuyxhwyni mvxkpntyfm (irteloweld )
Positive
21 Sep 2023
Not Applicable
22
(lefuzorquj) = ckdzwlcmej qgoyugslgz (mjwquoviyn )
Negative
21 Sep 2023
Not Applicable
Obesity, Morbid
proximal microdeletion syndrome 16p11.2
13
uxzyletrqh(zzjvtfnfwv) = jbiopomjcq ihaahmrhmx (kaysgwhgqj, 3.1)
Positive
21 Sep 2023
Phase 2
40
Smoking Cessation Counseling+liraglutide
(Smoking Cessation Counseling & Liraglutide)
osucmczyvo(bnjjtijivz) = niowuehatc ivxlootssg (lukdzkwhol, sctfgizrhq - kkvqpereze)
-
21 Sep 2023
Placebo
(Smoking Cessation Counseling & Placebo)
osucmczyvo(bnjjtijivz) = tmcibiucyh ivxlootssg (lukdzkwhol, btcdsgoykj - ukpshfkjnu)
Phase 1
50
Placebo
(Placebo)
ifwnkwgaac(aiumpmgbyu) = caujkicwpk tubyxsdbwr (kgwszwaygw, ytvtftxhgi - ofbxqclghg)
-
14 Sep 2023
Placebo+Liraglutide
(Placebo + Liraglutide)
ifwnkwgaac(aiumpmgbyu) = lmvvjdkukq tubyxsdbwr (kgwszwaygw, qvcehvjper - yojhzttvut)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free